Strong Financial Performance
Total sales increased 32% year-over-year, adjusted EBITDA rose 85%, and adjusted diluted EPS more than doubled. This reflects both top-line growth and improved operating leverage.
Animal Health Segment Growth
Animal Health segment led with 42% revenue growth, driven by a 68% increase in sales of newly integrated MFA and other products.
Nutritional Specialties and Performance Products
Nutritional Specialties showed 8% revenue growth, while Performance Products posted a strong gain of 28%.
Updated Financial Guidance
Full-year guidance was narrowed and the midpoint raised. Net sales are expected between $1.26 billion and $1.29 billion, with adjusted EBITDA of $177 million to $183 million, and adjusted EPS of $1.96 to $2.09.
Positive Free Cash Flow
Generated $49 million of positive free cash flow for the 12 months ended March 31, 2025.